Recombinant Human TNFRSF10C protein

中文名： 肿瘤坏死因子受体超家族成员10C(TNFRSF10C)重组蛋白
别名： TNFRSF10C；DCR1；Tumor necrosis factor receptor superfamily member 10C

货号: PA1000-3229

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>85%SDS-PAGE.
种属	Human
靶点	TNFRSF10C
Uniprot No	O14798
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	26-236aa
氨基酸序列	ATTAR QEEVPQQTVA PQQQRHSFKG EECPAGSHRS EHTGACNPCT EGVDYTNASN NEPSCFPCTV CKSDQKHKSS CTMTRDTVCQ CKEGTFRNEN SPEMCRKCSR CPSGEVQVSN CTSWDDIQCV EEFGANATVE TPAAEETMNT SPGTPAPAAE ETMNTSPGTP APAAEETMTT SPGTPAPAAE ETMTTSPGTP APAAEETMIT SPGTPA
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于TNFRSF10C重组蛋白的参考文献示例(内容为虚构，仅作格式参考)：

1. **"Structural characterization of recombinant TNFRSF10C and its ligand interaction"**

*作者：Smith J, et al.*

摘要：解析了TNFRSF10C重组蛋白的晶体结构，揭示了其胞外域与TRAIL配体结合的关键区域，为靶向凋亡通路的药物设计提供依据。

2. **"TNFRSF10C as a decoy receptor in cancer cell survival"**

*作者：Lee H, et al.*

摘要：通过体外实验证实，重组TNFRSF10C蛋白可竞争性结合TRAIL，抑制肿瘤细胞凋亡，提示其在癌症耐药性中的潜在作用。

3. **"High-yield expression and purification of functional TNFRSF10C in mammalian cells"**

*作者：Wang Y, et al.*

摘要：优化了哺乳动物细胞中TNFRSF10C重组蛋白的表达与纯化流程，获得高活性蛋白，适用于后续功能研究与筛选。

4. **"TNFRSF10C modulates immune response in chronic inflammation"**

*作者：Garcia R, et al.*

摘要：利用重组蛋白模型，发现TNFRSF10C通过调控NF-κB通路影响慢性炎症中的免疫细胞活性，为治疗自身免疫疾病提供新靶点。

(注：以上文献为示例，实际引用需以真实发表文章为准。)

背景信息

TNFRSF10C, also known as tumor necrosis factor receptor superfamily member 10C or TRAIL receptor 3 (TRAIL-R3), is a member of the TNF receptor family involved in regulating apoptosis and immune responses. It is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein that lacks a cytoplasmic death domain, distinguishing it from its pro-apoptotic counterparts TNFRSF10A (TRAIL-R1) and TNFRSF10B (TRAIL-R2). This structural feature enables TNFRSF10C to act as a decoy receptor by competitively binding to TNF-related apoptosis-inducing ligand (TRAIL), thereby inhibiting TRAIL-mediated apoptosis. This mechanism is critical in modulating cellular sensitivity to apoptosis, particularly in cancer cells where overexpression of TNFRSF10C may contribute to resistance to TRAIL-induced cell death.

Recombinant TNFRSF10C protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, including glycosylation and GPI anchoring. The purified protein retains the extracellular ligand-binding domain, enabling its use in studying receptor-ligand interactions, apoptosis regulation, and cancer biology. Researchers employ it as a competitive inhibitor in vitro to block TRAIL signaling pathways or to investigate its role in immune evasion by tumors. Additionally, it serves as a critical reagent in drug discovery for cancers resistant to TRAIL-based therapies, where targeting TNFRSF10C could restore apoptotic sensitivity. Quality assessments involve verifying binding affinity to TRAIL via surface plasmon resonance (SPR) or ELISA and confirming functional activity in apoptosis inhibition assays. Its therapeutic potential and diagnostic applications in oncology remain active areas of investigation.